Stock Analysts’ upgrades for Tuesday, July 7th:
AbCellera Biologics (NASDAQ:ABCL) was upgraded by analysts at Benchmark Co. from a hold rating to a buy rating. The firm currently has $11.00 target price on the stock.
Allegiant Travel (NASDAQ:ALGT) was upgraded by analysts at Melius Research from a hold rating to a buy rating. They currently have $160.00 target price on the stock.
CVS Health (NYSE:CVS) was upgraded by analysts at Wall Street Zen from a hold rating to a buy rating.
Keller Group (LON:KLR) was upgraded by analysts at Berenberg Bank to a buy rating. The firm currently has GBX 3,150 price target on the stock, up from their previous price target of GBX 2,550.
Meta Platforms (NASDAQ:META) was upgraded by analysts at Erste Group Bank AG from a hold rating to a buy rating.
MGM Resorts International (NYSE:MGM) was upgraded by analysts at Wells Fargo & Company from an underweight rating to an equal weight rating. Wells Fargo & Company currently has $48.30 price target on the stock.
Cloudflare (NYSE:NET) was upgraded by analysts at Scotiabank from a sector perform rating to a sector outperform rating. The firm currently has $300.00 target price on the stock, up from their previous target price of $225.00.
Ingevity (NYSE:NGVT) was upgraded by analysts at Wall Street Zen from a buy rating to a strong-buy rating.
Nestle (OTCMKTS:NSRGY) was upgraded by analysts at Erste Group Bank AG from a hold rating to a buy rating.
Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at Benchmark Co. from a hold rating to a buy rating. They currently have $185.00 target price on the stock.
Repligen (NASDAQ:RGEN) was upgraded by analysts at Benchmark Co. from a hold rating to a buy rating. They currently have $185.00 price target on the stock.
Ultra Clean (NASDAQ:UCTT) was upgraded by analysts at Wall Street Zen from a hold rating to a buy rating.
Waste Management (NYSE:WM) was upgraded by analysts at Canadian Imperial Bank of Commerce from a neutral rating to an outperformer rating. They currently have $244.00 price target on the stock.
Receive News & Ratings for AbCellera Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
